These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

379 related items for PubMed ID: 18587576

  • 1. Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration.
    Laurenti L, Tarnani M, De Padua L, Efremov DG, Zini G, Garzia M, Piccirillo N, Chiusolo P, Sorà F, Innocenti I, Sica S, Leone G.
    Ann Hematol; 2008 Nov; 87(11):891-8. PubMed ID: 18587576
    [Abstract] [Full Text] [Related]

  • 2. Comparison between oral and intravenous fludarabine plus cyclophosphamide regime as front-line therapy in patients affected by chronic lymphocytic leukaemia: influence of biological parameters on the clinical outcome.
    Laurenti L, De Padua L, Tarnani M, Piccirillo N, Falcucci P, D'Arena G, Innocenti I, Marietti S, Efremov DG, Chiusolo P, Zini G, Sora' F, Sica S, Leone G.
    Ann Hematol; 2011 Jan; 90(1):59-65. PubMed ID: 20625902
    [Abstract] [Full Text] [Related]

  • 3. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
    Bosch F, Ferrer A, Villamor N, González M, Briones J, González-Barca E, Abella E, Gardella S, Escoda L, Pérez-Ceballos E, Asensi A, Sayas MJ, Font L, Altés A, Muntañola A, Bertazzoni P, Rozman M, Aymerich M, Giné E, Montserrat E.
    Clin Cancer Res; 2008 Jan 01; 14(1):155-61. PubMed ID: 18172266
    [Abstract] [Full Text] [Related]

  • 4. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.
    Grever MR, Lucas DM, Dewald GW, Neuberg DS, Reed JC, Kitada S, Flinn IW, Tallman MS, Appelbaum FR, Larson RA, Paietta E, Jelinek DF, Gribben JG, Byrd JC.
    J Clin Oncol; 2007 Mar 01; 25(7):799-804. PubMed ID: 17283363
    [Abstract] [Full Text] [Related]

  • 5. [Prognostic significance of immunoglobulin variable region gene mutations in B-CLL patients treated with combination therapy fludarabine plus cyclophosphamide].
    Nikitin EA, Stadnik EA, Lorie IuIu, Biderman BV, Tsyba NN, Salogub GN, Kolosheĭnova TI, Kolosova LIu, Risinskaia NA, Zaritskiĭ IuA, Kovaleva LG, Sudarikov AB.
    Ter Arkh; 2007 Mar 01; 79(7):66-70. PubMed ID: 17802794
    [Abstract] [Full Text] [Related]

  • 6. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).
    Robak T, Jamroziak K, Gora-Tybor J, Stella-Holowiecka B, Konopka L, Ceglarek B, Warzocha K, Seferynska I, Piszcz J, Calbecka M, Kostyra A, Dwilewicz-Trojaczek J, Dmoszyñska A, Zawilska K, Hellmann A, Zdunczyk A, Potoczek S, Piotrowska M, Lewandowski K, Blonski JZ.
    J Clin Oncol; 2010 Apr 10; 28(11):1863-9. PubMed ID: 20212251
    [Abstract] [Full Text] [Related]

  • 7. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
    Byrd JC, Gribben JG, Peterson BL, Grever MR, Lozanski G, Lucas DM, Lampson B, Larson RA, Caligiuri MA, Heerema NA.
    J Clin Oncol; 2006 Jan 20; 24(3):437-43. PubMed ID: 16344317
    [Abstract] [Full Text] [Related]

  • 8. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
    Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM, Hussein MA, Appelbaum FR, Larson RA, Moore DF, Tallman MS.
    J Clin Oncol; 2007 Mar 01; 25(7):793-8. PubMed ID: 17283364
    [Abstract] [Full Text] [Related]

  • 9. Fludarabine combined with cyclophosphamid is highly effective in the treatment of chronic lymphocytic leukemia.
    Tóthová E, Kafková A, Fricová M, Guman T, Stecová N.
    Neoplasma; 2003 Mar 01; 50(6):433-7. PubMed ID: 14689065
    [Abstract] [Full Text] [Related]

  • 10. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.
    Marotta G, Bigazzi C, Lenoci M, Tozzi M, Bocchia M, Lauria F.
    Haematologica; 2000 Dec 01; 85(12):1268-70. PubMed ID: 11114133
    [Abstract] [Full Text] [Related]

  • 11. Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma.
    Sacchi S, Pozzi S, Marcheselli R, Federico M, Tucci A, Merli F, Orsucci L, Liberati M, Vallisa D, Brugiatelli M, Italian Lymphoma Study Group.
    Cancer; 2007 Jul 01; 110(1):121-8. PubMed ID: 17503433
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
    Robak T, Dmoszynska A, Solal-Céligny P, Warzocha K, Loscertales J, Catalano J, Afanasiev BV, Larratt L, Geisler CH, Montillo M, Zyuzgin I, Ganly PS, Dartigeas C, Rosta A, Maurer J, Mendila M, Saville MW, Valente N, Wenger MK, Moiseev SI.
    J Clin Oncol; 2010 Apr 01; 28(10):1756-65. PubMed ID: 20194844
    [Abstract] [Full Text] [Related]

  • 15. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.
    Bosch F, Abrisqueta P, Villamor N, Terol MJ, González-Barca E, Ferra C, González Diaz M, Abella E, Delgado J, Carbonell F, García Marco JA, Escoda L, Ferrer S, Monzó E, González Y, Estany C, Jarque I, Salamero O, Muntañola A, Montserrat E.
    J Clin Oncol; 2009 Sep 20; 27(27):4578-84. PubMed ID: 19704063
    [Abstract] [Full Text] [Related]

  • 16. p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV.
    Valgañón M, Giraldo P, Agirre X, Larráyoz MJ, Rubio-Martinez A, Rubio-Felix D, Calasanz MJ, Odero MD.
    Br J Haematol; 2005 Apr 20; 129(1):53-9. PubMed ID: 15801955
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide.
    Maloum K, Settegrana C, Chapiro E, Cazin B, Leprêtre S, Delmer A, Leporrier M, Dreyfus B, Tournilhac O, Mahe B, Nguyen-Khac F, Lesty C, Davi F, Merle-Béral H.
    Ann Hematol; 2009 Dec 20; 88(12):1215-21. PubMed ID: 19340428
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL).
    Ferrario A, Merli F, Luminari S, Stelitano C, Mannina D, Russo M, Mazza P, Marcheselli L, Goldaniga MC, Federico M, Baldini L, Gruppo Italiano per lo Studio dei Linfomi.
    Ann Hematol; 2011 Mar 20; 90(3):323-30. PubMed ID: 20848104
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.